Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737769 | 0.85 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL28676568 | 0.83 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL8098483 | 0.78 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL9873641 | 0.78 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL24689325 | 0.77 | HDAC6 (0.33) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL3126231 | 0.76 | DGAT1 (0.38) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL23452708 | 0.76 | DGAT1 (0.43) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL26691369 | 0.76 | CA14 (0.30) | HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL432112 | 0.75 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL25503461 | 0.75 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CA14DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188276-B1 | SUBSTITUTED HYDANTOINS | HOFFMANN LA ROCHE (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-7557221-B2 | Substituted hydantoins | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090048452-A1 | (R)-5-[4-(2-Hydroxy-ethoxy)-phenyl]-3-[(S)-1-(6-iodo-1H-benzoimidazol-2-yl)-2-phenyl-ethyl]-imidazolidine-2,4-dione; map kinase inhibitors; antihyperproliferative agents | CHEN SHAOQING | 2009-02-19 | — | — | US | disclosed |
| US-7045360-B2 | Method for analysis of reaction products | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-05-16 | — | — | US | disclosed |
| US-20020090728-A1 | Method for analysis of reaction products | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-07-11 | — | — | US | disclosed |
| WO-2001057526-A1 | METHOD FOR ANALYSIS OF REACTION PRODUCTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048452-A1 | (R)-5-[4-(2-Hydroxy-ethoxy)-phenyl]-3-[(S)-1-(6-iodo-1H-benzoimidazol-2-yl)-2-phenyl-ethyl]-imidazolidine-2,4-dione; map kinase inhibitors; antihyperproliferative agents | MAPK1, MAP3K2, MAP3K1 | HDAC6 3003/4885HDAC1 1039/4885HDAC2 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.